FARMINGDALE, N.Y., Aug. 5, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced the completion of product registration for its BoneScalpel™ Ultrasonic Bone Cutting System in Brazil. This follows the April 21, 2011, announcement of registration completion for the SonaStar® Surgical Aspiration System in Brazil. Open market sales have commenced for the SonaStar and it is expected that BoneScalpel will follow in the near future. Brazil is the largest market for medical devices in Latin America. Both BoneScalpel and the SonaStar are exclusively distributed in Brazil by Neuro Orthopaedics Surgeries, based near Rio de Janeiro. The Company entered into a distribution agreement with Neuro Orthopaedics on February 3, 2010. The SonaStar is used for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site. The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps. "Misonix is pleased with the outcome of the lengthy registration process required by the health ministry in Brazil. Latin America is a geographic market segment that Misonix has targeted for near-term sales growth and Brazil has a featured role in that plan," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are particularly pleased that two of our key products will be sold and distributed by Neuro Orthopaedics Surgeries in this very important market." About Misonix: Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com. With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.